Health
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
- Chemical process enhances room temperature stability - - Provisional patent applications filed - PURCHASE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that the American Chemical Society journal Organic Process Research & Development has published a manuscript describing the novel chemical process used to manufacture zervimesi
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3G97CJjBroOGRUYevL.t.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"- Chemical process enhances room temperature stability -","length":56,"tagName":"p"},{"type":"text","content":" - Provisional patent applications filed -","length":41,"tagName":"p"},{"type":"text","content":"PURCHASE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that the American Chemical Society journal Organic Process Research & Development has published a manuscript describing the novel chemical process used to manufacture zervimesine (CT1812). With this new manufacturing process, Cognition will be able to produce materials for future clinical studies of zervimesine. In addition, if zervimesine is approved, this process is expected to support commercial manufacturing needs. Provisional patent applications covering this chemical process and a preferred polymorphic form of zervimesine have been filed.","length":784,"tagName":"p"},{"type":"text","content":"“The chemical process described in this manuscript leverages innovative technologies such as high throughput screening and light-induced, continuous flow processing to more efficiently and safely synthesize zervimesine,” explained Steven A. Weissman, Ph.D., head of CMC at Cognition Therapeutics. “We have also identified a novel crystal form, or polymorph, of zervimesine that has improved stability at room temperature, enabling a long shelf life, as well as other beneficial pharmaceutical properties. Polymorphs contain the same molecular components as the parent compound but are arranged in a different configuration.”","length":624,"tagName":"p"},{"type":"text","content":"About Zervimesine (CT1812)Zervimesine (CT1812) is an investigational oral, once-daily pill being...